2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
- 26 August 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (41), 4229-4361
- https://doi.org/10.1093/eurheartj/ehac244
Abstract
No abstract availableThis publication has 828 references indexed in Scilit:
- Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2012
- Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosisProceedings of the National Academy of Sciences of the United States of America, 2012
- Adjuvant Trastuzumab in HER2-Positive Breast CancerThe New England Journal of Medicine, 2011
- Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factorsAnnals of Oncology, 2011
- Anthracycline-Induced Cardiomyopathy: Clinical Relevance and Response to Pharmacologic TherapyJournal of the American College of Cardiology, 2010
- Drug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug developmentEuropean Journal of Cancer, 2008
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007
- Medical Assessment of Adverse Health Outcomes in Long-term Survivors of Childhood CancerJAMA, 2007
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002